Vascular-targeted carriers (VTCs) are an emerging area of research within particulate drug delivery. We define VTCs as particles designed with surface adhesive ligands that mimic those of leukocytes. During inflammation, activated endothelial cells (ECs) upregulate surface leukocyte adhesion molecules (LAMs), including selectins, intercellular adhesion molecule-1 (ICAM), and vascular cell adhesion molecule-1. 9 Importantly, ECs shed their glycocalyx barrier, enabling leukocytes to interact directly with the EC surface. 10 Surface ligands on circulating leukocytes facilitate rolling on and firm capture to activated ECs and assist in extravasation into tissue to perform various immune functions. 11 This leukocyte adhesion cascade (LAC) is an important mechanism for normal immune function, but is also indicative of excessive cell recruitment that occurs early in many diseases. 9, 11 Overexpression of LAMs represent potential targets for the design of particulate therapeutics; VTCs have been designed utilizing a wide range of LAM-LR pairs for novel therapeutic approaches in atherosclerosis 12, 13 and cancerous tumors, 14 among others. 2, 6, [15] [16] [17] Success of VTCs relies heavily on LR interactions with overexpressed LAMs on diseased ECs. VTCs are unique in that they must adhere to diseased ECs under rapid blood flow conditions, unlike other particles targeted to tissue spaces. Once localized to the endothelium, the interactions between LR pairs dictate adhesion and ultimate drug carrier efficacy. VTC and EC surface bonds must form rapidly to overcome particle momentum in flow. Capture and firm arrest at the surface will depend on the kinetics of the LR engaged pair and the aggregate strength of those interactions. Particle ligand total receptor avidity and specificity must be balanced; excessive avidity can lead to off target binding and immune responses due to rapid opsonization of non-native proteins, while insufficient LR avidity can result in minimal binding. 18 The design of VTC ligands must correspond with receptors in the targeted disease state; a ligand for the immediate onset of disease may not function efficiently in a chronic response. 19, 20 Given the fluctuation of receptors on ECs and the presence of blood flow, leukocytes achieve adhesion with multiple LR pairs, where each LR pair provides a unique benefit of capture, firm adhesion, or transmigration, based on spatiotemporal expression on the diseased ECs. Notably, selectin receptors facilitate leukocyte capture and rolling, yet physiological levels of this LR pair are not enough to achieve firm adhesion on inflamed ECs. Firm adhesion requires secondary LR pairs, usually involving cell adhesion molecules (CAMs), which are expressed at a lower EC surface density with more favorable kinetics for firm adhesion. 9, 11 Through the synergistic effects of these two LR pairs, leukocytes efficiently respond to inflammation on diseased tissues in vivo.
Despite the goal of LAC mimicry, the use of multiple LAM ligands on VTCs remains poorly understood. Most studies of VTCs have focused on particle designs with a single LR pair, with emphasis on the final disease outcome due to the delivered drug. Efficacy studies that have probed dual ligands are largely qualitative, comparing multiligand particles to the single ligand counterparts with minimal control over the total particle ligand presentation. 5, 18, [21] [22] [23] Additional studies have probed the importance of ligand ratios between two LR pairs in static conditions, which fail to capture LR pair dynamics under physiologically relevant flows. 21, 24 To study LR kinetics under flow, multiple research groups have used protein-coated plates to study the adhesion and rolling of dual-targeted particles in vitro. [25] [26] [27] [28] [29] [30] However, these studies lack the complexity of a true diseased endothelium, as spatiotemporal LAM expression varies widely. 31 To address these gaps in understanding, we have designed 500-nm polystyrene spheres with controlled ligand densities and evaluated particle adhesion in physiological environments. Polystyrene particles serve as model VTCs in this work as it enables evaluation of ligand surface properties on a monodisperse particle population; we anticipate the particle dynamics observed here will be applicable to translatable particle formulations, such as poly(lactic-co-glycolic acid). While the 500 nm size is just outside the 100-200 nm range typically considered for drug delivery, 500-nm spheres offer easier surface modification, 
where h is the channel height (0.0127 cm), w the channel width (0.25 cm), and Q the volumetric flow rate (mL/s). Q was calculated as 82 mL/min in this system. The h of 127 mm and g w of 200 s 21 were chosen to mimic the flow profile within a vein/venule of similar dimensions to those studied via intravital microscopy. 40, 41 After blood perfusion of 5 min, PBS buffer containing 1% BSA was added to PPFC and particle adhesion densities were assessed via optical imaging using a
Nikon TE-2000-S inverted microscope with a digital camera (Photometrics CoolSNAP EZ with a Sony CCD sensor). Due to the addition of buffer flow, only adherent particles are quantified in this assay.
Results were imaged and analyzed via NIS-ElementsV R analysis software and ImageJ.
| Intravital fluorescence microscopy
Visualization of mesentery vessels was performed as previously described. 42, 43 Briefly, female mice (3-4 weeks old) were anesthetized and a tail vein catheter placed for delivery of particles. Mice were placed on a custom-made microscope heated stage at 37°C, and the mesentery was exteriorized to a glass cover slip via midline incision. Analysis was performed using Slidebook 6 and ImageJ using blinded file names. Particle rolling velocities were obtained using particle tracking software, and all paths were manually confirmed until at least 50 particles were tracked per experimental condition. Vessels were isolated and measured using Slidebook 6. Particles found in adjacent vessels but within the frame were excluded from the analysis.
Particles were considered adherent when they appeared in the same location for 10 consecutive frames of the particle tracking. Particles were considered rolling when their tracked paths moved less than 50
mm between frames. Firmly adhered particles did not contribute to the rolling velocity data.
| Particle adhesion simulation
Particle adhesion was simulated in a two-dimensional rectangular channel using COMSOL 5.2 through a combined continuum and particulate model, adapted from previous work and described in detail in the Supporting Information Material. 30, 44 Briefly, a velocity profile was established for an incompressible Newtonian fluid in a rectangular channel with dimensions 10 3 30 lm, with a reactive surface of 10 lm along the bottom wall. Unless otherwise designated, a WSR of 200 s 21 was imposed (average channel velocity 1.67 mm/s). A continuum model was developed to evaluate particle transport, considering both convection and diffusion and solved using the convectiondiffusion equation,
where C is the particle concentration and D is the particle mass diffusivity. The LR interaction at the reactive surface was treated with a general form boundary PDE, the governing equation being:
where B is the number of bound particles on the reactive surface and 
where c to evaluate k a and k d :
where d is a representative length, chosen to be the diameter of the particle. 44 Using the derived reaction boundary condition, B was determined as a function of time, 
| Statistics
Characterization of HUVEC expression after TNF-a activation is repre- 
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3.1 | Density of sLe A dictates particle adhesion in vitro and in vivo
We utilized a PPFC assay to investigate the role of sLe A density on particle adhesion under physiological blood flow conditions. A series of four particle types (A-D) was prepared with increasing sLe A surface density ( Figure 1A ). SLe A site densities were quantified by flow cytometry (Table 1) Figure 1C ). Increasing the sLe A density on 500-nm particles from 5,000 to 40,000 sites/mm 2 resulted in increased particle adhesion. We observed a 2-fold increase in particle binding from A to B; additional sLe A on C and D resulted in further increased adhesion (3-and 6-fold increases over A, respectively).
We were interested if the increase in sLe A site density could produce a similar increase in particle binding in vivo, which we observed with real-time intravital fluorescence microscopy. 2), which resulted in more firmly bound particles; particle C was the most effective, with a 30-fold increase of total adherent particles over A (p = .014). This corresponded to a 30-fold increase in rolling particles and a 20-fold increase in firmly arrested particles (p = .012 and p = .042, respectively).
Additionally, particle C produced a 9-fold increase in total adherent particles over B (p = .019), with a 7.5-fold increase in number of rolling particles and a 10-fold increase in firmly arrested particles (p = .019
and p = .051, respectively). We observed no statistical difference between particles C and D for either rolling or firmly arrested particles, however, the average number of adherent particles was less for particle D (p < .05 for all interactions Figure 3 , to determine if particle adhesion from a dual-targeted particle is merely the sum from the two individual ligands. The adhesion and rolling propensity of these particles were evaluated in the in vivo model of acute mesentery inflammation, as before.
As shown in Figure 3A , particles A and E had 5,000 sites/mm 2 of sLe A or aICAM, respectively, while particle F was the direct sum of the two ligands, for a total site density of 10,000 sites/mm 2 ( Table 1) However, combining sites of sLe A and aICAM on the same particle Figure 1 . (F) resulted in a significant increase of adherent particles at the wall (7-fold increase over A, p = .005, and 3-fold increase over E, p = .012). For particle F, the number of firmly arrested particles was a 5-fold (p = .034) and 3-fold (p = .049) increase over A and E, respectively. No differences were observed in the number of rolling particles between groups, however, there were differences in rolling velocities.
Particle A had the fastest rolling velocity, while particle F had the slowest rolling velocity, corresponding to the most effective adhesion at the wall. A video of particle type F adhering in vivo can be found in Supporting Information Video 4. With particle types A, E, and F, a decrease in observed particle rolling velocity corresponded to more particle adhesion at the vessel wall in vivo.
To probe the effect of total site density, we investigated particles B, G, and H, which each had twice the site densities of particles A, E, and F, respectively ( Figure 3B ). At these higher total site densities, varying the ligand from sLe A (B) to aICAM (G) produced a minimal increase of particle presence at the wall, in either firmly arrested or rolling numbers, neither of which were significant from observation for particles A and E. Again, combining sites of sLe A and aICAM on the same particle (H) resulted in a significant increase of adherent particles at the wall (2-fold increase over B, p = .039, and 3-fold increase over G, p = .030). The number of firmly arrested particles of type H resulted in a 4.3-fold (p = .007) and 3-fold (p = .011) increase over E and G, respectively. The relationship between rolling velocity and total particle adhesion was not linear in Figure 3B , owing to the fact that no particles were detected rolling for particle type G. Interestingly, increasing the total site density of dual-targeted particles from 10,000
(F) to 20,000 (H) sites/mm 2 did not provide a significant increase in adhesion (p = .5).
Particle adhesion of both dual-targeted particle types (F, H) indicates a more than additive effect of each individual-targeting ligand.
We further compared the benefit of dual-targeting ligands on a single particle by keeping the total number of sites constant in order to eliminate any possible enhancement due to the change in total density (as studied in Figure 3 ). We developed a series of five particles with a constant total of 10,000 sites/mm 2 , given the lack of benefit when increasing to 20,000 sites/mm 2 (F, H). We varied ratios of sLe A and aICAM ( Figure 4A and Table 1 ) and tested these in the model of Figure 4B is a representative image of the highest dual-targeted fluorescent particle binding in vivo. Representative movies of particle types F, I, and J can be found in Supporting Information Videos 4-6, respectively. For all five particle types, the number density of both rolling and firmly arrested particles is quantified in Figure 4C . The ligand combination on particle I resulted in a significantly increased number of firmly arrested particles compared to all other combinations (p < .001 for all comparisons), with at least a 3-fold increase over all other ligand combinations. Similar numbers of rolling particles were observed with all five conditions; however, as shown in Figure 4D , slight decreases in rolling velocities were observed for particles I and F compared to B and J.
| Optimal dual ligand ratio on particle varies with EC surface expression
Given the dramatic increase in adhesion of particle I in vivo over all other ligand combinations in the particle series ( Figure 4A ), we investigated the dependence of particle adhesion on the corresponding surface expression of LAMs on the endothelium. As shown in Figure 5A and Supporting Information Figure 4 , TNF-a activation of HUVECs resulted in elevated levels of both ICAM and E-selectin surface expression, albeit maximally at different times. Basal levels of ICAM were observed in all three conditions, while no basal E-selectin was observed. We further quantified these changes in expression level over time using flow cytometry (representative gating in Supporting Information Figure 5 ), with fold changes over unactivated cells shown in Figure 5B . Maximum E-selectin was observed between 4 and 8 hr, while maximum ICAM expression was observed at 24 hr. With maximum E-selectin expression, there was elevated ICAM expression, with the inverse true for E-selectin at time points of maximum ICAM expression. We explored particle adhesion of the panel of five particle types from Figure 4A in a PPFC with activated HUVECs at 4 hr ( Figure   5C ) and 24 hr ( Figure 5D ) to probe the importance of HUVEC surface expression on particle adhesion. At 4 hr, particle J resulted in superior particle adhesion, corresponding to 1.5-fold more bound particles than all other particle types (p < .05 between J and particles I, F, and G). At 24
hr, particle I resulted in maximal particle adhesion, with 6-fold more bound particles over all other particle types (p < .0001 between all particle types).
To further explore these LR-pair interactions, we developed a computational model of binding at an endothelial surface, taking into account the number of ligands on the particle (N L -aICAM, N L -sLe A ), Figure 6A ). The k a decreases slightly with increasing shear rate, while k d increases over five orders of magnitude between tested shear rates of 10 and 1,000 s
21
. The dependency of k a and k d on shear rate translates to differences in particle adhesion at the surface, as shown in Supporting Information Figure 6A .
Using this model, we probed the differences in particle adhesion Having shown that our model could accurately capture the binding dynamics at the reactive surface for both LAMs, we compared the binding efficiencies of the particle series shown in Figure 4A Figure 6B ). Figure   6 highlights the complex interplay between ligand and receptor densities combined with receptor-ligand kinetics. For each particle type, 
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Despite studies successfully employing dual-targeted particles for vascular delivery, gaps still remain in understanding the effect of varied particle ligand densities and ratios. Here, we report a distinct interplay between endothelial receptor expression and particle ligand patterning that determines particle adhesion. To our knowledge, this is the first report of intravital microscopy investigations of dual-targeting VTCs in vivo, thus allowing evaluation of both particle rolling and firm adhesion. We find that increasing the number of sites of sLe A on particles increases adhesion in vitro and in vivo. We also find that the dual- In both our in vitro and in vivo results, increasing sLe A densities produced increased adhesion. This increase in single ligand density also slowed the rolling velocity of particles, which has previously been demonstrated for sLe A functionalized particles over a coated surface. 45 As more LR pair interactions occur, the aggregate LR interaction forces overcome the wall shear force to establish firm adhesion. Avidin's multivalency increases the likelihood of clustered targeting ligands, yet our surface densities never saturated the available avidin sites (Supporting Information Figure 2 ). General increases in ligand density increases the likelihood of a viable spatial orientation that favors LR interactions.
However, there were diminishing returns to adding more sLe A on the particle surface in vivo. Other researchers have discussed the steric hindrance limit of antibody ligands, such that too many antibodies on a particle surface block each other from successful interaction with endothelial receptors. 46, 47 Although sLe A is a small carbohydrate unlikely to cause steric hindrance, our results indicate a similar trend,
showing a clear limit of diminishing returns of particle adhesion with increasing site density. Adding more sites of sLe A did not significantly hinder particle adhesion over the range of densities tested, but, these data disprove the mantra that "the more, the better" for particle ligands.
The dual-ligand VTC particles studied here target both the selectin and b 2 integrin mediated paths of adhesion to inflamed endothelium. Most previous work in dual ligand particles explores targeting inflammatory surface molecules with mixes of antibodies. 18, 21, 22, 48 Our work aims to explore a dynamic mixing of a carbohydrateselectin LR pair with an antibody-CAM LR pair, which have drastically different kinetics. 34, 35 We first explored the benefit of having two ligands on a single particle, to determine if particle adhesion from a dual-targeted particle is merely the sum from the two different ligands. To answer this, we evaluated the series of particles shown in Figure 3 . In vivo, increasing the total ligand density of either sole ligand type from 5,000 to 10,000 sites/mm 2 resulted in nonsignificant increases in either firmly arrested (A-B, E-G) or rolling (A-B, E-G) particles. When we compare these individual ligand types to dualtargeted particles F and H, we can conclude that there is a more than additive effect when blending the two ligand types. For example, the total number of adhesive particles for dual-targeted particle F is more than the addition of particle A and E; this is also true when comparing of the single-ligand particle types. As explained with the rolling velocities, this is likely due to the synergistic activity of the two ligands; sLe A facilitates initial adhesion, but the rapid off rate guarantees some level of particle rolling, 34 while aICAM facilitates firm adhesion after an initial interaction. 35 When both ligands are present, the behaviors blend to allow initial rolling and eventual firm capture, similar to leukocytes. Various investigations into leukocyte adhesion in vivo have demonstrated the importance of endothelial expression of both selectins and CAMs on cell rolling and adhesion. [49] [50] [51] [52] Providing a variety in the ligand presentation on particles corresponding to physiological ratios of endothelial receptors provides additive benefits for VTCs targeting a dynamic endothelium.
As Figures 1-2 , and 6B demonstrate, increasing the total site density can increase particle adhesion both in vitro, in vivo, and in silico.
To eliminate the suspicion that comparative observations in Figure 3 are purely due to the increased total site density, we compared particles of the same total ligand density (10,000 sites/mm 2 ), as shown in
Figures 4-6. Our results show that an optimal particle ligand ratio exists based on the surface expression of the endothelium, where the most effective particle type has a blend of both ligands and a ratio favoring the least expressed receptor. These results were initially counterintuitive. At maximum expression of E-selectin (4 hr, Figure   5C ), we hypothesized that the sLe A /E-selectin interaction would control particle adhesion, with greater amounts of sLe A resulting in greater adhesion to the dominant receptor. Instead, our results show the most adhesion for particle J, with 25% sLe A :75% aICAM. A parallel trend was observed at maximum expression of ICAM (24 hr, Figure 5D ), where the most adhesion was achieved with particle I, with 75% sLe A :25% aICAM. Furthermore, the in vivo results shown in Figure 4C match this adhesion trend in Figure 5D . The receptor profile was not explicitly quantified in the mesentery, but it is known that rapid inflammation induced by topical TNF-a results in P-selectin expression within minutes of stimulation, in addition to omnipresent basal levels of ICAM. 53, 54 SLe A binds nonspecifically to all selectins, facilitating the adhesive sLe A -selectin LR pair interaction. Although uncharacterized, the total number of ICAM receptors is likely higher than P-selectin within our short, 3 min activation. 55 Combined, these in vitro and in vivo data support the conclusion that the best ligand design of a particle is dependent on the surface expression of the ECs, showing better adhesion with more ligand for the lesser-expressed receptor.
These results are further explained by the in silico model. While could be readily applied to other combinations of LR pairs to predict particle adhesion; the corresponding receptor densities of a given surface would allow comparison between particle designs in order to determine the particle with the highest binding potential.
Few studies have delved deeply into the direct effect of each LR pair on multitargeted particles. 30, 35, 48 Of those, there has been in vitro research corroborating that particle adhesion and rolling velocities depend on both the receptor density, as represented by coated plate coverage, and the particle ligand density. 35, 56 In these coated plate studies, particles with increasing amounts of aICAM provided improved firm binding regardless of dominant plate receptor composition. 28 Particles functionalized in these studies had ligand site densities typically less than 1,000 sites/mm 2 . 35 Our in vitro findings further differ in three key ways, utilizing TNF-a activated ECs rather than receptor coated plates, 500-nm particles instead of 6 mm, and whole blood in place of buffer flow, all of which more closely capture the physiological dynamics at the surface of the vascular wall. Our in vitro findings are also supported by recent work with 2-mm particles coated with variable ratios of the antibody ligands aICAM and anti-E-selectin, where optimal binding was achieved by a particle of 70:30 aICAM:anti-E-selectin ligand composition following 4-hr HUVEC activation. 48 Unfortunately, the total ligand site density was not evaluated in this study. Here, we attribute the success of this particle combination to the surface receptor expression, rather than the cited geometry of the flow channel. This work on larger, 2-mm particles suggests that the same optimal presentation of ligands on the particle can be extended to particles of different sizes.
Optimization of VTC particle designs that utilize dual targeting is expected to provide improved delivery to the vascular wall. As demonstrated via intravital microscopy, the dual-targeted VTCs studied here rapidly and efficiently adhere to the inflamed endothelium. Impor- 
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Overall, the work presented here represents a truly novel demonstration of particle binding to an inflamed mesentery via intravital microscopy.
We have shown that the adhesive abilities of 500 nm particles, which are not preferentially excluded to the vascular wall from blood flow, can be significantly improved by targeting ligand design. While the total number of sites of a single ligand can drive particle adhesion to the endothelium, combining LR pairs from multiple LAM interactions provides a more powerful approach. These dual-targeted ligand designs should be optimized based on the surface endothelium, with ligand coating densities favoring the less-predominant adhesive receptor, as driven by the LR pair kinetics. The knowledge presented here about the importance of the LR pair matching will help in the intelligent particle ligand design for future applications in all diseases benefitting from VTCs, including atherosclerosis, cancer, inflammation, and many more.
